If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 10 of 18
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
Objective
A phase 1 Study evaluating NX-5948, a BTK Degrader in Adults with Relapsed Refractory B-cell Malignancies
Protocol No
NURIX-NX-5948-301
Categories
A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial
Objective
Comparing cytarabine + daunorubicin therapy versus cytarabine + daunorubicin + venetoclax versus venetoclax + azacitidine in younger patients with intermediate risk AML
Protocol No
CCTG-MM1YA-CTG01
Categories
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
Objective
Prospective, Observational Study of Participants at Risk for CGVHD
Protocol No
INCYTE-MA-GVHD-401-THRIVE
Categories
Phase I Study of LV20.19 CAR T-Cells in Combination with Pirtobrutinib for Relapsed, Refractory B-Cell Malignancies
Objective
Phase I Study of LV20.19 CAR T-Cells in Combination with Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Protocol No
IIT-SHAH-PIRTO
Categories
Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination with Ziftomenib (KO-539) or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination with Ziftomenib for the Treatment of Patients with Acute Myeloid Leukemia
Objective
Study of ziftomenib in combination with venetoclax or chemotherapy for treatment of AML patients
Protocol No
KURA-KO-MEN-007
Categories
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Trans
Objective
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
Protocol No
CTN-2203
Categories
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Phnegative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly-Diagnosed Older Adults or Adults With Relapsed or Refractory Disease and Feasibility Study of Ponatinib Wi
Objective
A Phase 2 Study of Inotuzamab Ozogamicin in Patients with ALL in Newly Diagnosed Adults
Protocol No
ALLIANCE-A041703
Categories
An Open-Label, Multi-Center Asciminib Roll-Over Study to Assess Long-Term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment
Objective
A Phase 3b Study of ABL001 in Patients who have Completed a Novartis Sponsored Asciminib Trial
Protocol No
NOVARTIS-CABL001A2001B
Categories
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Patient With Previously Untreated Chronic Lymphocytic Leukemia
Objective
A Study of BGB-11417 plus BGB-3111 in Patients with Previously Untreated Chronic Lympho-cytic Leukemia
Protocol No
BEONE-BGB-11417-304
Categories
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients with Myeloid Malignancies
Objective
A Phase 1b/2 Study of BGB-11417 in Patients with Myeloid Malignancies
Protocol No
BEIGENE-BGB-11417-103
Categories